Skip to main navigation Skip to search Skip to main content

Author Correction: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial (Nature Medicine, (2022), 28, 10, (2155-2161), 10.1038/s41591-022-01962-5)

  • LCMC study investigators
  • , Jamie E. Chaft
  • , Filiz Oezkan
  • , Mark G. Kris
  • , Paul A. Bunn
  • , Ignacio I. Wistuba
  • , David J. Kwiatkowski
  • , Dwight H. Owen
  • , Yan Tang
  • , Bruce E. Johnson
  • , Jay M. Lee
  • , Gerard Lozanski
  • , Maciej Pietrzak
  • , Michal Seweryn
  • , Woo Yul Byun
  • , Katja Schulze
  • , Alan Nicholas
  • , Ann Johnson
  • , Jessica Grindheim
  • , Stephanie Hilz
    • David S. Shames, Chris Rivard, Eric Toloza, Eric B. Haura, Ciaran J. McNamee, G. Alexander Patterson, Saiama N. Waqar, Valerie W. Rusch, David P. Carbone, Saiama N. Waqar, Elaine Shum, Misako Nagasaka, Marianna Koczywas, Edward B. Garon, David J. Finley, David R. Camidge, Jennifer W. Carlisle, Justin D. Blasberg

Research output: Contribution to journal › Comment/debate

6   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'Author Correction: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial (Nature Medicine, (2022), 28, 10, (2155-2161), 10.1038/s41591-022-01962-5)'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry

Keyphrases